Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 4, 2010, Pages 270-277

  Chay, Wen Yee ^a   Tan, Sze Huey ^b   Lo, Yew Long ^c   Ong, Simon Yew Kwang ^a   Ng, Hui Cheng ^a   Gao, Fei ^b   Koo, Wen Hsin ^a   Choo, Su Pin ^a  

^a Department of Medical Oncology ^*  (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

Calcium; Magnesium; Nerve conduction study; Oxaliplatin neuropathy; Paresthesia

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GLUCONATE CALCIUM; MAGNESIUM SULFATE; OXALIPLATIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFUSION; MALE; MULTIPLE CYCLE TREATMENT; NERVE CONDUCTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM GLUCONATE; COHORT STUDIES; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MAGNESIUM SULFATE; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PARESTHESIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649766509     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01344.x     Document Type: Article

References (20)

1. Gramont A, De Figer A, Seymour M etal. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
2. Giacchetti S, Perpoint B, Zidani R etal. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.
3. André T, Boni C, Mounedji-Boudiaf L etal. Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators etal. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
4. Gamelin L, Boisdron-Celle M, Delva R etal. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10: (12 Pt 1) 4055-61.
5. Cersosimo R. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005; 39: 128-35.
6. Armstrong CM, Cota G. Calcium block of Na+ channels and its effect on closing rate. Proc Natl Acad Sci U S A 1999; 96: 4154-7.
7. Fayers PM, Machin D. Quality of Life: Assessment, Analysis and Interpretation. Chichester: Wiley, 2000; 45-70.
8. Hochster HS, Grothey A, Shpilsky A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neuropathy. J Clin Oncol 2008; 26: 1188-9.
9. Grothey A, Hart LL, Rowland KM etal. Intermittent oxaliplatin administration and time-to-treatment failure in metastatic colorectal cancer: final results of the phase III CONcePT trial. J Clin Oncol 2008; 26: (May 20 suppl; abstr 4010).
10. Nikcevich DA, Grothey A, Sloan JA etal. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. J Clin Oncol 2008; 26: May 20 suppl; abstr 4009.
11. Gamelin L, Boisdron-Celle M, Poirier AL, Berger V, Morel A, Gamelin E. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26: 1188-9.
12. Luo FR, Wyrick SD, Chaney SG. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransforma-tion products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 1999; 44: 29-38.
13. Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res 1998; 10: (11-12): 595-603.
14. Cavaletti G, Tredici G, Petruccioli MG etal. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001; 37: 2457-63.
15. Holmes J, Stanko J, Varchenko M etal. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 1998; 46: 342-51.
16. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 5 (Suppl 15): 21-33.
17. Lersch C, Schmelz R, Eckel F etal. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002; 2: 54-8.
18. Cascinu S, Catalano V, Cordella L etal. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20: 3478-83.
19. Argyriou AA, Polychronopoulos P, Chroni E. The usefulness of nerve conduction studies in objectively assessing oxaliplatin-induced peripheral neuropathy. Oncologist 2007; 12: 1371-2
20. Andre T, Bensmaine MA, Louvet C etal. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560-8.